Integrated BioPharma, Inc.
INBP · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8% | -0.7% | -9.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 10.2% | 7.7% | 8% | 11.6% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 6.2% | 2.9% | 2.5% | 6.3% |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 1.5% | 0.2% | -0.1% | 6.8% |
| EPS Diluted | 0.026 | 0.004 | -0.001 | 0.12 |
| % Growth | 619.4% | 427.3% | -100.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |